Clinical Trials Logo

Metastatic Disease clinical trials

View clinical trials related to Metastatic Disease.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05188911 Recruiting - Prostate Cancer Clinical Trials

Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial

Start date: July 15, 2020
Phase:
Study type: Observational

By incorporating dual-tracer PET/CT (PSMA and FDG) and ctDNA, we aimed to evaluate lesion heterogeneity and genomic change of mCRPC patients receiving novel hormonal therapy. The relationship between treatment response and different molecular characterization, as well as imaging features would also be evaluated.

NCT ID: NCT04492735 Recruiting - Metastatic Disease Clinical Trials

The Use of Indocyanine Green as a Diagnostic Adjunct for Pediatric Solid Malignancies

Start date: June 5, 2020
Phase:
Study type: Observational

Use of indocyanine green will augment the accuracy of identification and resection of both primary solid malignancies as well as their pulmonary metastases, where applicable We will conduct a prospective feasibility study of pediatric patients with solid malignancies with or without lung metastatases who present at the time of initial diagnosis or relapse. These patients will receive a targeted dye to aid in the resection of these metastases. We plan to assess ICG as it relates to: 1. Diagnostic accuracy using pathologic correlation as gold standard measure 2. Short and long term event free and overall survival

NCT ID: NCT03632005 Recruiting - Spinal Cord Injury Clinical Trials

Negative Pressure Wound Therapy vs. Sterile Dressing for Patients Undergoing Thoracolumbar Spine Surgery

Start date: March 18, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if the use of the Prevena™ System decreases the rate of subcutaneous seroma, superficial wound dehiscence and infection.

NCT ID: NCT00406900 Recruiting - Melanoma Clinical Trials

Melanoma Inhibitory Activity (MIA): A Serological Marker for Metastatic Uveal Melanoma

Start date: January 1999
Phase: N/A
Study type: Observational

Uveal Melanoma is the most common primary intraocular tumor in adults. Most tumors metastasize to the liver. So far no sensitive or specific serological tumor marker is routinely used. The marker "Melanoma inhibitory activity" is a promising marker. Study hypothesis is to detect metastatic lesions in an early stage. This would increase life expectance of our patients